Sonata Software

Soft operating print; healthy order intake

5



Information Technology >

Result Update >

date > July 31, 2025

Sonata posted yet another quarter of weak operating performance in Q1. IITS revenue was below our estimate, declining 0.9% QoQ CC. IITS EBITDAM inched up by 10bps QoQ to 16.6%, albeit below expectations. Sonata secured three major deals in Q1, including the USD73mn TCV with a US-based TMT client. It reported total order bookings of USD105mn and book-to-bill ratio of 1.28x. Growth during Q1 was led by a large TMT deal ramp-up, continued strength in HLS, and demand for data and AI services. However, performance was impacted by softness in retail and manufacturing, budget pressures at a key BFSI client, and broader macroeconomic slowdown. Domestic business faced the impact of a slowdown in the IT/ITeS sector, and several OEMs planned the shift to a direct engagement model for large clients. The management refrained from providing specific growth outlook, citing challenges in RMD, a large BFSI client, and macro uncertainty. However, it remains hopeful of positive revenue growth in IITS in FY26. It expects to achieve near-20% EBITDAM in IITS by FY26-end, led by large deal ramp-ups, improved utilization, offshore shift, and pyramid rationalization. Factoring in the dismal Q1 performance, we cut FY26-28E EPS by 1-9%. We retain BUY with unchanged TP of Rs475 at 22x Jun-27E EPS.

Results summary

IITS revenue grew 0.6% QoQ to USD81.8mn (down 0.9% CC), a tad below our estimate of USD82mn. Among verticals, TMT and HLS grew 15.0% and 17.4%, while RMD, BFSI, and Emerging declined 2.6%, 12.5%, and 32.9% QoQ, respectively. Among geographies, Europe declined 5.3% QoQ, while the US and RoW grew 0.6% and 11.8%. IITS EBITDAM was up by 10bps QoQ to 16.6%. Overall EBITDAM declined by 120bps QoQ to 5.4%, missing our estimate by 6.6%. IITS headcount grew 0.4% QoQ to 6,393. LTM attrition inched up QoQ to 16% (vs 14% in Q4). Gross contribution fell 12.6% QoQ in the domestic business, mainly due to seasonality, softness in IT and ITeS, and margin pressure from focus on new customer acquisition, as a large OEM plans to go direct. SSOF declared an interim dividend of Rs1.25/sh. **What we like:** Deal intake, TMT growth. **What we do not like:** Revenue/margin miss, client-specific issues in BFSI and Hi-tech.

Earnings call KTAs

1) The BFSI vertical faced growth challenges due to budget-related constraints and cost pressures from a large client. The management expects weakness to persist in a large client in Q2 as well, which could weigh on BFSI growth. It indicated that apart from this client-specific issue, BFSI is doing well. However, it refrained from providing any outlook on BFSI growth, considering the uncertainty over recovery in the large client. 2) The RMD vertical continues to face challenges due to tariff uncertainties and regulatory changes, with potential for further negative impact...(contd)...

Sonata Software: Financial Snapshot (Consolidated)										
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E					
Revenue	86,131	101,573	105,578	116,443	132,616					
EBITDA	7,274	6,892	6,679	8,855	10,069					
Adj. PAT	4,832	4,247	4,259	5,902	7,084					
Adj. EPS (Rs)	17.2	15.1	15.2	21.0	25.3					
EBITDA margin (%)	8.4	6.8	6.3	7.6	7.6					
EBITDA growth (%)	20.4	(5.2)	(3.1)	32.6	13.7					
Adj. EPS growth (%)	6.9	(12.1)	0.3	38.6	20.0					
RoE (%)	35.7	27.3	23.0	26.8	26.7					
RoIC (%)	46.5	34.1	24.9	30.9	35.6					
P/E (x)	37.6	27.3	27.3	19.7	16.4					
EV/EBITDA (x)	16.1	This report	17.6	for Tooms 13.3	hito Margue					
P/B (x)	8.3	6.8	is intended 5.8	tor ream vv	hite Marque					
FCFF yield (%)	2.4	4.9	2.8	4.4	5.5					

Source: Company, Emkay Research

ın-26
-
BUY
BUY
14.7

mkay

Stock Data	SSOF IN
52-week High (Rs)	764
52-week Low (Rs)	286
Shares outstanding (mn)	280.4
Market-cap (Rs bn)	116
Market-cap (USD mn)	1,328
Net-debt, FY26E (Rs mn)	3,125.8
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	1,933.3
ADTV-3M (USD mn)	22.1
Free float (%)	69.2
Nifty-50	24,855.1
INR/USD	87.4
Shareholding,Jun-25	
Promoters (%)	28.2
FPIs/MFs (%)	9.7/25.6

Price Performance							
(%)	1M	3M	12M				
Absolute	1.0	(1.8)	(45.0)				
Rel. to Nifty	3.6	(3.9)	(45.0)				



Dipeshkumar Mehta

dipeshkumar.mehta@emkayglobal.com +91-22-66121253

Jimit Gandhi

jimit.gandhi@emkayglobal.com +91-22-66121255

Shivang Bagla shivang.bagla@emkayglobal.com +91-22-66242491 ...(contd)...3) In the healthcare vertical, Sonata is able to disintermediate and dislodge incumbent vendors, especially on the pharmacy side, due to its capabilities in data and AI. 4) It has recently hired heads of its retail and manufacturing vertical as well as its BFSI vertical in the US, for strengthening its sales leadership. 5) Sonata has significantly increased its contribution in the BFSI and HLS verticals, both now comprising over 30% of revenue (up from 13% three years ago). 6) The management is focusing on i) consistently securing large deals and large accounts, ii) expanding in BFSI and HLS, and iii) deepening capabilities in data AI and modernization engineering. 7) Pipeline for AI was ~USD46mn in Q1. AI order book stood at USD8.2mn. Pipeline for Microsoft Fabric is USD39mn. 8) To negate the impact of a large OEM planning to go direct, the company is making progress across four strategic areas, which are: a) new partnerships and wins with AWS, Google, Oracle, etc; b) scaling security operations center for India-based clients; c) accelerating growth through the Microsoft SMC channel; and d) winning large integrated SITs that combine platform engineering and services. 9) Quant performance exceeded the original target, although it was lower than the revised target. It has signed a new agreement with incremental performance obligations for three years. 10) As of Q1FY26, cash stood at Rs6bn, down from Rs7bn in Q4, mainly due to Quant earnout payout and loan instalment repayments. Net cash was negative at Rs625mn. The company has taken an additional USD35mn loan in the guarter. 11) It plans to pay a quarterly interim dividend from this year. 12) Wage hike will be implemented in phases – junior/middle management from Aug-25, and senior management from Oct-25.

Update on AI/Gen AI

1) The company expects AI-enabled services to contribute 20% of revenue over the next three years. It is actively pursuing AI-led opportunities across >100 clients and is working toward AI opportunities across engineering, industry differentiation solutions, and internal operations. 2) Sonata launched AgentBridge, making it one of the first mid-tier firms with enterprise-grade agentic AI workflows. 3) In engineering, Sonata deploys its platform Harmoni.AI workbench to embed AI into client delivery, and uses IntellQA, an AI-powered automated test-case generation platform. 4) Around 95% of the workforce is trained in AI.

Exhibit 1: Q	Quarterly	snapshot
--------------	-----------	----------

(Rs mn)	Q1FY26	Q4FY25	QoQ (%)	Q1FY25	YoY (%)
IITS revenue (USD mn)	81.8	81.3	0.6	82.7	(1.1)
Net sales	29,652	26,172	13.3	25,274	17.3
Operating expenses	28,055	24,445		23,513	
EBITDA	1,597	1,727	(7.5)	1,762	(9.4)
- Margin (%)	5.4	6.6	(120.0)	7.0	(160.0)
Depreciation	261	230		333	
EBIT	1,336	1,496	(10.7)	1,429	(6.5)
- Margin (%)	4.5	5.7	(120.0)	5.7	(110.0)
Interest paid	51	101		200	
Other income	242	112		189	
Pre-tax profit	1,527	1,508	1.3	1,417	
Tax provided	434	432		361	
Profit after tax	1,093	1,075		1,056	
Emkay Net profit	1,093	1,075	1.7	1,056	3.5
EPS (Rs)	3.9	3.8	1.7	3.8	3.5

Source: Company, Emkay Research

Exhibit 2: Actuals vs estimates

.	Estimate Variation				iation	
(Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Sales	82	82		-0.4%		Revenue came ahead of expectations due to beat in the domestic business. However, IITS revenue missed estimates.
EBIT	29,652	27,318	27,385	8.5%	8.3%	
EBIT margin	1,336	1,523	This reno 1,400	-12.3%	nded for Te -4.6%	Margin missed estimates due to pricing pressure in the domestic business and the margin miss in IITS.
PAT	4.5%	5.6%	5.1%	-110 bps	-60 bps	Profit missed estimates due to the operating performance miss.

Source: Company, Bloomberg, Emkay Research

Exhibit 3: Changes in estimates

(0	FY26E			FY27E			FY28E		
(Rs mn)	Old	New	Chg	Old	New	Chg	Old	New	Chg
IITS - Revenue (USD mn)	344.3	336.3	-2.3%	388.9	376.7	-3.2%	439.8	425.5	-3.2%
Revenue	103,910	105,578	1.6%	114,995	116,443	1.3%	130,999	132,616	1.2%
EBIT	6,274	5,577	-11.1%	7,796	7,758	-0.5%	8,992	9,001	0.1%
EBIT margin	6.0%	5.3%		6.8%	6.7%		6.9%	6.8%	
Net profit	4,683	4,259	-9.0%	6,057	5,902	-2.6%	7,185	7,084	-1.4%
EPS (Rs)	16.7	15.2	-9.0%	21.6	21.0	-2.6%	25.6	25.3	-1.4%

Source: Company, Emkay Research

Exhibit 4: SSOF - One-year forward PER Price — −22x -**2**9x 1,000 900 800 700 600 (Rs) 500 400 300 200 100 Jan-15 Jan-16 -Jul-16 Jan-17 -Jul-17 -Jan-18 -Jul-18 -Jan-19 -Jul-19 -Jan-20 Jul-20 -Jan-22 · Jul-21 Jan-23 Jan-21

Source: Company, Emkay Research

][

Sonata Software: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	86,131	101,573	105,578	116,443	132,616
Revenue growth (%)	15.6	17.9	3.9	10.3	13.9
EBITDA	7,274	6,892	6,679	8,855	10,069
EBITDA growth (%)	20.4	(5.2)	(3.1)	32.6	13.7
Depreciation & Amortization	1,319	1,215	1,102	1,097	1,068
EBIT	5,955	5,678	5,577	7,758	9,001
EBIT growth (%)	9.3	(4.7)	(1.8)	39.1	16.0
Other operating income	-	-	-	-	-
Other income	1,256	712	584	495	678
Financial expense	850	653	413	384	234
PBT	6,360	5,737	5,748	7,869	9,445
Extraordinary items	(1,747)	0	0	0	0
Taxes	1,529	1,490	1,489	1,967	2,361
Minority interest	0	0	0	0	0
Income from JV/Associates	-	-	-	-	-
Reported PAT	3,085	4,247	4,259	5,902	7,084
PAT growth (%)	(31.7)	37.7	0.3	38.6	20.0
Adjusted PAT	4,832	4,247	4,259	5,902	7,084
Diluted EPS (Rs)	17.2	15.1	15.2	21.0	25.3
Diluted EPS growth (%)	6.9	(12.1)	0.3	38.6	20.0
DPS (Rs)	7.8	4.4	4.9	6.3	7.5
Dividend payout (%)	71.0	28.9	32.6	30.1	29.8
EBITDA margin (%)	8.4	6.8	6.3	7.6	7.6
EBIT margin (%)	6.9	5.6	5.3	6.7	6.8
Effective tax rate (%)	24.0	26.0	25.9	25.0	25.0
NOPLAT (pre-IndAS)	4,524	4,203	4,133	5,818	6,750
Shares outstanding (mn)	280	280	280	280	280

Source: Company, Emkay Research

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	278	278	278	278	278
Reserves & Surplus	13,785	16,782	19,653	23,778	28,752
Net worth	14,063	17,059	19,930	24,056	29,029
Minority interests	0	0	0	0	0
Non-current liab. & prov.	355	137	(791)	(1,514)	(2,097)
Total debt	6,743	4,416	5,119	3,619	1,119
Total liabilities & equity	22,073	22,357	25,003	26,905	28,796
Net tangible fixed assets	1,327	1,036	969	1,008	1,066
Net intangible assets	4,248	3,862	3,528	2,915	2,430
Net ROU assets	810	636	577	595	651
Capital WIP	0	0	0	0	0
Goodwill	11,135	11,397	11,397	11,397	11,397
Investments [JV/Associates]	5,740	3,880	3,536	3,536	3,536
Cash & equivalents	5,360	3,100	1,993	3,838	5,644
Current assets (ex-cash)	22,796	23,421	24,446	26,998	30,366
Current Liab. & Prov.	28,534	24,339	20,867	22,786	25,642
NWC (ex-cash)	(5,738)	(918)	3,579	4,212	4,724
Total assets	22,073	22,097	24,883	26,905	28,796
Net debt	1,383	1,316	3,126	(219)	(4,525)
Capital employed	22,073	22,357	25,003	26,905	28,796
Invested capital	10,163	14,481	18,777	18,937	18,966
BVPS (Rs)	50.1	60.8	71.1	85.8	103.5
Net Debt/Equity (x)	0.1	0.1	0.2	-	(0.2)
Net Debt/EBITDA (x)	0.2	0.2	0.5	-	(0.4)
Interest coverage (x)	8.5	9.8	14.9	21.5	41.4
RoCE (%)	37.2	30.2	26.5	31.3	33.5

Balance Sheet

Cash flows					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	4,614	5,737	5,748	7,869	9,445
Others (non-cash items)	2,908	1,312	1,102	1,097	1,068
Taxes paid	(2,623)	(1,636)	(2,417)	(2,690)	(2,943)
Change in NWC	(2,094)	1,030	(404)	(633)	(512)
Operating cash flow	2,805	6,443	4,029	5,643	7,058
Capital expenditure	1	(678)	(702)	(522)	(642)
Acquisition of business	(726)	(5,919)	(4,093)	0	0
Interest & dividend income	332	213	0	0	0
Investing cash flow	(543)	(4,356)	(4,451)	(522)	(642)
Equity raised/(repaid)	36	35	0	0	0
Debt raised/(repaid)	1,726	(2,465)	703	(1,500)	(2,500)
Payment of lease liabilities	(334)	(293)	0	0	0
Interest paid	(324)	(384)	0	0	0
Dividend paid (incl tax)	(2,189)	(1,226)	(1,388)	(1,777)	(2,110)
Others	0	0	0	0	0
Financing cash flow	(1,085)	(4,333)	(685)	(3,277)	(4,610)
Net chg in Cash	1,177	(2,246)	(1,107)	1,844	1,806
OCF	2,805	6,443	4,029	5,643	7,058
Adj. OCF (w/o NWC chg.)	4,900	5,413	4,433	6,276	7,570
FCFF	2,806	5,766	3,327	5,121	6,416
FCFE	2,289	5,326	2,913	4,738	6,182
OCF/EBITDA (%)	38.6	93.5	60.3	63.7	70.1
FCFE/PAT (%)	74.2	125.4	68.4	80.3	87.3
FCFF/NOPLAT (%)	62.0	137.2	80.5	88.0	95.0

Source: Company, Emkay Research

Valuations and key Ratios									
Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E				
P/E (x)	37.6	27.3	27.3	19.7	16.4				
EV/CE(x)	5.6	5.5	4.7	4.2	3.9				
P/B (x)	8.3	6.8	5.8	4.8	4.0				
EV/Sales (x)	1.4	1.2	1.1	1.0	0.9				
EV/EBITDA (x)	16.1	17.0	17.6	13.3	11.7				
EV/EBIT(x)	19.7	20.7	21.1	15.1	13.1				
EV/IC (x)	11.6	8.1	6.3	6.2	6.2				
FCFF yield (%)	2.4	4.9	2.8	4.4	5.5				
FCFE yield (%)	2.0	4.6	2.5	4.1	5.3				
Dividend yield (%)	1.9	1.1	1.2	1.5	1.8				
DuPont-RoE split									
Net profit margin (%)	5.6	4.2	4.0	5.1	5.3				
Total asset turnover (x)	4.3	4.8	4.6	4.6	4.9				
Assets/Equity (x)	1.5	1.4	1.2	1.2	1.0				
RoE (%)	35.7	27.3	23.0	26.8	26.7				
DuPont-RoIC									
NOPLAT margin (%)	5.3	4.1	3.9	5.0	5.1				
IC turnover (x)	8.9	8.2	6.3	6.2	7.0				
RoIC (%)	46.5	34.1	24.9	30.9	35.6				
Operating metrics									
Core NWC days	(24.3)	(3.3)	12.4	13.2	13.0				
Total NWC days	(24.3)	(3.3)	12.4	13.2	13.0				
Fixed asset turnover	4.9	5.7	5.7	6.2	6.9				
Opex-to-revenue (%)	24.0	23.5	23.0	23.0	23.0				

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Closing Price (INR)	TP (INR)	Rating	Analyst
410	475	Buy	Dipeshkumar Mehta
393	475	Buy	Dipeshkumar Mehta
346	500	Buy	Dipeshkumar Mehta
489	700	Buy	Dipeshkumar Mehta
605	780	Buy	Dipeshkumar Mehta
670	780	Buy	Dipeshkumar Mehta
	410 393 346 489 605	Price (INR) IP (INR) 410 475 393 475 346 500 489 700 605 780	Price (INR) IP (INR) Rating 410 475 Buy 393 475 Buy 346 500 Buy 489 700 Buy 605 780 Buy

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions(team.emkay@whitemarquesolution

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 31, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 31, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 31, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution)

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions(team.emkay@whitemarquesolution